A single modular platform — scalable, programmable, and designed to outsmart cancer.
Our Pipeline
Melanoma
Harnessing ViVac’s RNA–Lipid Nanoparticle platform to provoke potent intratumoral immune activation in one of the most immunogenic solid tumors, aiming for durable control and systemic tumor regression.
Glioblastoma (GBM)
Applying targeted RNA–Lipid Nanoparticle delivery to penetrate the brain tumor microenvironment and trigger localized antiviral-like immune responses against this highly resistant cancer.
Ovarian Cancer
Targeting CD155-overexpressing ovarian tumors with self-limiting RNA–Lipid Nanoparticle therapy designed to reshape the tumor microenvironment and sustain immune surveillance against recurrence.
Together, these programs demonstrate the versatility of ViVac’s platform — adaptable across a broad range of solid tumors where localized immune activation can achieve lasting therapeutic benefit.
Proof-of-Concept
ViVac has achieved strong early validation of its RNA–Lipid Nanoparticle platform, demonstrating proof-of-concept in vitro and confirming RNA expression and targeted tumor delivery in vivo.
